

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Vignia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/678,682	10/03/2000	Gerald Juergen Roth	5/1275	6798
23703 7:	590 06/13/2003	•		
BOEHRINGER INGELHEIM CORPORATION			EXAMINER	
900 RIDGEBURY ROAD P O BOX 368 RIDGEFIELD, CT 06877			LIU, HONG	
RIDGEI IEED,	C1 00077		ART UNIT	PAPER NUMBER
			. 1624	110
			DATE MAILED: 06/13/2003	1 1/2
			¥ .	/

Please find below and/or attached an Office communication concerning this application or proceeding.

,	Applicati n No.	Applicant(s)			
	09/678,682	ROTH ET AL.			
Office Action Summary	Examiner	Art Unit			
	Hong Liu	1624			
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply					
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). Status					
1) Responsive to communication(s) filed on <u>06 M</u>	<u>flay 2003</u> .				
2a)⊠ This action is FINAL . 2b)□ Thi	is action is non-final.				
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.					
Disposition of Claims 4)⊠ Claim(s) 1-7 is/are pending in the application.					
4a) Of the above claim(s) <u>8</u> is/are withdrawn from consideration.					
5) Claim(s) is/are allowed.					
6)⊠ Claim(s) <u>1-7</u> is/are rejected.					
7) Claim(s) is/are objected to.					
8) Claim(s) are subject to restriction and/or	election requirement.				
Application Papers					
9) The specification is objected to by the Examiner	·.				
10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.					
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).					
11)☐ The proposed drawing correction filed on is: a)☐ approved b)☐ disapproved by the Examiner.					
If approved, corrected drawings are required in reply to this Office action.					
12)☐ The oath or declaration is objected to by the Examiner.					
Priority under 35 U.S.C. §§ 119 and 120					
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).					
a)☐ All b)☐ Some * c)☐ None of:					
1. Certified copies of the priority documents have been received.					
2. Certified copies of the priority documents have been received in Application No					
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 					
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).					
a) The translation of the foreign language provisional application has been received. 15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.					
Attachment(s)					
 Notice of References Cited (PTO-892) Notice of Draftsperson's Patent Drawing Review (PTO-948) Information Disclosure Statement(s) (PTO-1449) Paper No(s) <u>5</u> 	5) Notice of Informal F	(PTO-413) Paper No(s) Patent Application (PTO-152)			

Claims 1-8 are pending in this application.

This action is in response to the applicants' amendment and reply filed on May 16, 2003.

Response to Arguments

DETAILED ACTION

Applicants' arguments and amendments filed on May 16, 2003 have been fully considered. The amended claims, however, are not completely free of prior art.

The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

Claim Rejections - 35 USC § 112

The rejection of claims under 35 U.S.C., 112, first paragraph, is hereby withdrawn in view of applicant's amendments.

The rejection of claims under 35 U.S.C., 112, second paragraph, is hereby withdrawn in view of applicant's arguments and amendments.

Claim Rejections - 35 USC § 103

The rejection of claims 1-7 under 35 U.S.C., 103(a) as being unpatentable over Davis et al. (WO 99/15500) is hereby withdrawn in view of applicants' amendment of R2 which excludes the functional group of di-alkyl aminocarbonyl.

Claims 1-7 are rejected under 35 U.S.C. 103(a) as being unpatentable over Grell et al. (US 6,043,254). The reference teaches a generic group of indolinones which embraces applicant's instantly claimed compounds. See formula I, Col. 3 wherein R1 can be

Application/Control Number: 09/678,682 Page 3

Art Unit: 1624

alkanoylamino, alkoxycarbonylamino (which corresponds to the definition of R2 of the present invention), R3 can be phenyl substituted with Het wherein Het is a 5-membered heteroaromatic ring, etc. The compounds are taught to be useful as kinase-inhibitors. The claims differ from the reference by reciting a specific species and/or a more limited genus than the reference. However, it would have nevertheless been obvious to one skilled in the art at the time of the invention to be motivated to select any of the species of the genus taught by the reference including those instantly claimed, because the skilled chemist would have the reasonable expectation that any of the specie of the genus would have similar properties and, thus, the same use as taught for the genus as a whole, i.e., kinase inhibitors. One of ordinary skill in the art would have been motivated to select the claimed compounds from the genus in the reference since such compounds would have been suggested by the reference as a whole. It has been held that a prior art disclosed genus of useful compounds is sufficient to render prima facie obvious a species falling within a genus. See In re Susi, 440 F.2d 442, 169 USPQ 423, 425 (CCPA 1971), followed by the Federal Circuit in Merck & Co. V. Biocraft Laboratories, 847 F.2d 804, 10 USPQ 2d 1843, 1846 (Fed. Cir. 1989).

Conclusion

1. Applicant's submission of an information disclosure statement prompted the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 609(B)(2)(i). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

Application/Control Number: 09/678,682

Art Unit: 1624

Page 4

MONTHS from the mailing date of this action. In the event a first reply is filed within TWO

A shortened statutory period for reply to this final action is set to expire THREE

MONTHS of the mailing date of this final action and the advisory action is not mailed until after

the end of the THREE-MONTH shortened statutory period, then the shortened statutory period

will expire on the date the advisory action is mailed, and any extension fee pursuant to 37

CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event,

however, will the statutory period for reply expire later than SIX MONTHS from the mailing

date of this final action.

Any inquiry concerning this communication should be directed to Examiner Hong Liu

whose telephone number is (703) 306-5814. The examiner can normally be reached on Monday

through Friday from 8:30 AM to 6:00 PM. If attempts to reach the examiner by the phone are

unsuccessful, the examiner's supervisor, Mukund Shah can be reached at (703) 308-4716. The

fax phone number for this group is (703) 308-4734 for "unofficial" purposes and the actual

number for official business is (703) 308-4556. Any inquiry of a general nature or relating to the

status of this application or proceeding should be directed to the Group receptionist whose

number is (703) 308-1235.

hl

June 11, 2003

M-Churanny

Mukund Shah

Supervisory Patent Examiner

Art Unit 1624